A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at Georgetown University’s Lombardi Comprehensive Cancer Center report that ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Northwestern Medicine scientists have identified the cellular mechanisms that cause immune cells to differentiate and ultimately lose function during viral infection, findings that could improve ...

A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...